You have read all your free articles, to continue reading subscribe to read the rest of this content.
Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an antibiotic-free treatment for vaginal infections. This pilot study marks the start of a clinical development program of a treatment with dual effect, targeting boAlready a subscriber Login You have read…
Bavarian Nordic has announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV in older adults. The VANIR trial is a global, randomized, double-blind Phase 3 trial of the recombinant MVA-BN RAlready a subscriber Login…
Futility analysis in PLIANT study completed and approved by the DSMB, states Pledpharma. The futility/safety analysis of the first 30 patients has been completed and that no negative impact on the anticancer effect of the chemotherapy drug has been observed. The analysis covers the first 30 paAlready a subscriber Login…
New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga, compared to placebo, in patients with heart failure (HF). The reduction in risk of cardiovascular (CV) death was consistent across pre-specifieAlready a subscriber Login You have read all…
